Physician profile
Kwon Kim
NPI 1376064097
$1,775.07
in general payments reported to CMS, 2019-2025
16 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $45.59 · 2024: $89.65 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $246.34 | 2024-2025 | Filspari |
| Amgen INC. | $209.17 | 2025 | Krystexxa, Repatha, Otezla |
| Calliditas Therapeutics US INC. | $192.71 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $171.57 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $164.03 | 2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.86 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $119.28 | 2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $101.81 | 2025 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $99.10 | 2025 | |
| Aurinia Pharma U.S., INC. | $66.13 | 2025 | Lupkynis |
| Vifor Pharma, INC. | $64.45 | 2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $46.67 | 2023-2025 | |
| Novo Nordisk INC | $46.39 | 2025 | Wegovy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $35.53 | 2025 | Voyxact |
| Lilly USA, LLC | $34.19 | 2025 | Mounjaro, Zepbound |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $20.84 | 2023 | Nxstage System One |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kwon Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.